TDZ antagonizes MLL-AF6–mediated leukemia progression. (A) Tumor growth in mice that received flank injections of SHI-1, HL60, or THP1 cells and were treated daily with TDZ at 8 mg/kg, compared with the control group treated with DMSO (n = 6). The gray area indicates the treatment interval. (B) Cell death (annexin V⁺, PI⁺, and annexin V⁺/PI⁺) of SHI-1–injected mice treated with TDZ 16 hours after MLL-AF6 chimera silencing (sir), evaluated 8, 24, and 30 hours after treatment, compared with DMSO (n = 2). Data are the mean ± SEM. *P < .05; **P < .01; ***P < .001; ****P < .0001.